Omnicell (NASDAQ: OMCL) reported Q4 EPS of $0.91, $0.11 better than the analyst estimate of $0.80. Revenue for the quarter came in at $249.2 million versus the consensus estimate of $245.5 million.

“We had a strong fourth quarter and full year 2020, consistent with the preliminary results we announced last month. We are pleased to have exceeded our pre-pandemic bookings guidance and October 2020 guidance across all key metrics, including total revenues, total product bookings, and non-GAAP earnings per share, and ended the year with record product bookings of more than $1 billion,” stated Randall Lipps, Chairman, President, Chief Executive Officer, and founder of Omnicell. “We made tremendous progress advancing the autonomous pharmacy as we continued expanding our portfolio and investing in developing a single, cloud-based platform that can connect nearly all of our devices. The pandemic highlighted the need for increased digitization and virtualization of processes throughout the healthcare system, underscoring the strategic relevance of Omnicell’s solutions. Pharmacy automation is becoming increasingly important, and that is reflected in the robust and growing demand for our offerings. Looking ahead, I believe we are well-positioned to continue driving growth in our business and delivering value for our shareholders as we support our healthcare partners on their journey to the autonomous pharmacy.”

GUIDANCE:

Omnicell sees Q1 2021 EPS of $0.64-$0.69, versus the consensus of $0.72. Omnicell sees Q1 2021 revenue of $243-248 million, versus the consensus of $250.1 million.

Omnicell sees FY2021 EPS of $3.40-$3.60, versus the consensus of $3.44. Omnicell sees FY2021 revenue of $1.09-1.15 billion, versus the consensus of $1.09 billion.

For earnings history and earnings-related data on Omnicell (OMCL) click here.